Overall rank by patents
#3,448
Across all tracked assignees
USPTO PatentsView assignee record - 107 granted patents across 1 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G02C (SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES).
The verdict
Costa holds 107 US patents across 1 technology areas, rank #3,448 of 50,000 tracked assignees.
Costa Del Mar, Inc. has been granted 107 US utility patents between 2015 and 2025, placing Costa Del Mar, Inc. at rank #3,448 across all assignees tracked by PlainPatent. This portfolio spans 1 distinct Cooperative Patent Classification (CPC) subclasses, averaging 1.5 claims per patent with primary concentration in G02C (SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES). As a US Corporation, Costa Del Mar, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Costa sits between Aurora Labs Ltd. (107 patents, rank #3,444) and Galderma Research & Development (107 patents, rank #3,452) - the closest US assignees by grant volume. The composite Innovation Score of 21.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 11 grants, compared with 96 in the 2015–2019 window, a -89% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Costa Del Mar, Inc.'s 1.5 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 1 subclass reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Costa Del Mar, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Aurora Labs Ltd.
107 patents
BCE Inc.
107 patents
Bestop, Inc.
107 patents
Boston Scientific Medical Device Limited
107 patents
Cylance Inc.
107 patents
Diebold Nixdorf Incorporated
107 patents
Elbit Systems Ltd.
107 patents
GALDERMA RESEARCH & DEVELOPMENT
107 patents
Costa Del Mar, Inc.
107 patents
What this shows Costa holds 107 patents at rank #3,448, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #3,448 in granted patent volume.
Other assignees with the most granted patents in Costa's primary technology class.
Costa's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
21 Top 92% higher than 8% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 27 | 25.2% |
| 2016 | 22 | 20.6% |
| 2017 | 1 | 0.9% |
| 2018 | 7 | 6.5% |
| 2019 | 39 | 36.4% |
| 2020 | 3 | 2.8% |
| 2021 | 1 | 0.9% |
| 2023 | 1 | 0.9% |
| 2024 | 2 | 1.9% |
| 2025 | 4 | 3.7% |
Top 1 of 1 technology areas
Overall rank by patents
#3,448
Across all tracked assignees
21.1 out of 100
How to use this portfolio
Costa's 107 grants land it in the top 92% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.